Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

NCT01339923 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01339923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01339923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2014
Enrollment
1,409 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease, meningococcal meningitis